Vyera Pharmaceuticals
Vyera Pharmaceuticals (formerly Turing Pharmaceuticals) is a pharmaceutical company incorporated in Zug, Switzerland, with offices in New York City. The company started to do business in the US as Vyera Pharmaceuticals in September 2017.
| Company type | Private |
|---|---|
| Industry | Pharmaceuticals |
| Founded | February 2015 |
| Founder | |
| Headquarters | New York City and Zug, Switzerland |
Key people | Justin Garrett Chief Executive Officer |
| Products | Vecamyl, Daraprim |
| Website | www |
The company has two marketed products: Daraprim (pyrimethamine), for the treatment of toxoplasmosis, and Vecamyl (mecamylamine hydrochloride) for the treatment of hypertension. The company was widely criticized for raising the price of daraprim by 5456% following its acquisition of rights to the drug in 2015. After the price raise of the drug, the company's stocks dropped around 10%. CEO Martin Shkreli faced immense criticism for his actions. The company was named after Alan Turing, the computer scientist.
On May 10, 2023, Vyera filed for Chapter 11 bankruptcy.